Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Brisbane-based Medtech developer ImpediMed (IPD) has received further clearance for its SOZO technology from the FDA
  • This clearance enables ImpediMed to market SOZO for assessing patients at risk of protein-calorie malnutrition
  • SOZO delivers a precise snapshot of a patient’s fluid status and tissue composition in less than 30 seconds
  • ImpediMed is up 11.1 per cent this morning with shares trading for 20 cents apiece

Brisbane-based Medtech developer ImpediMed (IPD) has received further clearance for its SOZO technology from the U.S. Food and Drug Administration (FDA).

The 510(k) clearance enables ImpediMed to market SOZO for assessing patients that are at risk of protein-calorie malnutrition (PCM).

It also tracks clinically relevant body composition parameters over time in healthy and unhealthy patient populations.

Specifically, the claims around PCM are to aid clinicians who are using Subjective Global Assessment (SGA) tools to assess patients at risk of PCM.

SGA tools, such as the American Society for Parental and Enteral Nutrition (A.S.P.E.N.) guidelines, define changes in physical attributes as assessment criteria for PCM in patients.

Weight, muscle and fat mass are tracked and reported by SOZO and can be used by clinicians to support their diagnosis and assessment and diagnosis of PCM.

PCM is a form of malnutrition, defined as a range of pathological conditions that arise from a lack of dietary protein and energy in varying proportions.

The disease is fairly common in both children and adults and accounts for six million deaths annually.

SOZO is the world’s most advanced, noninvasive bioimpedance spectroscopy (BIS) device.

The technology assesses patients with secondary lymphedema to deliver a precise snapshot of fluid status and tissue composition in less than 30 seconds.

A single SOZO reading allows clinicians across multiple specialities to provide individualised, proactive care that can help improve patient outcomes.

“We are pleased that this submission to the FDA included real-world evidence. This clearance will expand our clinical utility and footprint in the oncology space,” ImpediMed Managing Director and CEO Richard Carreon commented.

ImpediMed’s share price is up 11.1 per cent this morning with shares trading for 20 cents apiece at 11:31 am AEDT.

IPD by the numbers
More From The Market Herald
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion Group (ASX:ALC) extends contract with Sydney Local Health District

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).